QuantRx Announces Phase I Clinical Trial for BFPET

QuantRx Biomedical Corporation … announced that FluoroPharma, Inc., a company developing breakthrough cardiovascular molecular imaging agents for the PET market, is commencing Phase I clinical trials for BFPET following institutional review board (IRB) approval of the proposed studies.
Centre Daily Times